Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18196094 | 0.77 | GAA (0.37) | ALDH1A1TSHR | |
| SCHEMBL3053611 | 0.74 | — | — | |
| SCHEMBL7240619 | 0.69 | TSHR (0.32) | ALDH1A1TSHR | |
| SCHEMBL503261 | 0.66 | — | — | |
| SCHEMBL1085851 | 0.66 | — | — | |
| SCHEMBL1576713 | 0.66 | — | — | |
| SCHEMBL27580997 | 0.65 | TSHR (0.38) | ALDH1A1TSHR | |
| SCHEMBL297859 | 0.63 | — | — | |
| SCHEMBL12168243 | 0.62 | TSHR (0.40) | ALDH1A1TSHR | |
| SCHEMBL4258568 | 0.62 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7776838-B1 | Treatment of chemotherapeutic agent and antiviral agent toxicity with acylated pyrimidine nucleosides | WELLSTAT THERAPEUTICS CORPORATION (US) | 2010-08-17 | — | — | US | disclosed |
| US-7709459-B2 | Pyrimidine nucleotide precursors for treatment of systemic inflammation and inflammatory hepatitis | WELLSTAT THERAPEUTICS CORPORATION (US) | 2010-05-04 | — | — | US | disclosed |
| US-7307166-B1 | Oxpurine nucleosides and their congeners, and acyl, derivatives thereof, for improvement of hematopoiesis | WELLSTAT THERAPEUTICS CORPORATION (US) | 2007-12-11 | — | — | US | disclosed |
| US-7173017-B1 | Antiinflammatory agents and treatment of hepatitis with pyrimidine nucleotides to prevent liver damage | WELLSTAT THERAPEUTICS CORPORATION (US) | 2007-02-06 | — | — | US | disclosed |
| US-7166581-B1 | Treatment of chemotherapeutic agent and antiviral agent toxicity with acylated pyrimidine nucleosides | WELLSTAT THERAPEUTICS CORPORATION (US) | 2007-01-23 | — | — | US | disclosed |
| EP-1491201-B1 | Methods of reducing toxicity of 5-fluorouracil with acylated pyrimidine nucleosides | WELLSTAT THERAPEUTICS CORP (US) | 2006-03-22 | — | — | EP | disclosed |
| US-20040235782-A1 | Oxypurine nucleosides and their congeners, and acyl derivatives thereof, for improvement of hematopoiesis | PRO-NEURON, INC. | 2004-11-25 | — | — | US | disclosed |
| US-20040220134-A1 | Pyrimidine nucleotide precursors for treatment of systemic inflammation and inflammatory hepatitis | PRO-NEURON, INC. (US) | 2004-11-04 | — | — | US | disclosed |
| EP-0768883-A4 | PYRIMIDINE NUCLEOTIDE PRECURSORS FOR TREATMENT OF SYSTEMIC INFLAMMATION AND INFLAMMATORY HEPATITIS | WELLSTAT THERAPEUTICS CORP (US) | 2004-09-15 | — | — | EP | disclosed |
| US-20030212036-A1 | Pyrimidine nucleotide precursors for treatment of systemic inflammation and inflammatory heptitis | PRO NEURON, INC. | 2003-11-13 | — | — | US | disclosed |
| WO-1996040165-A1 | METHODS OF REDUCING TOXICITY OF CHEMOTHERAPEUTIC AND ANTIVIRAL AGENTS WITH ACYLATED PYRIMIDINE NUCLEOSIDES | PRO-NEURON, INC. (US) | 1996-12-19 | — | — | WO | disclosed |
| EP-0570519-A4 | OXYPURINE NUCLEOSIDES AND THEIR CONGENERS, AND ACYL DERIVATIVES THEREOF, FOR IMPROVEMENT OF HEMATOPOIESIS | PRO NEURON INC (US) | 1996-02-21 | — | — | EP | disclosed |
| WO-1996001115-A1 | PYRIMIDINE NUCLEOTIDE PRECURSORS FOR TREATMENT OF SYSTEMIC INFLAMMATION AND INFLAMMATORY HEPATITIS | PRO-NEURON, INC. (US) | 1996-01-18 | — | — | WO | disclosed |
| EP-0594667-A4 | TREATMENT OF CHEMOTHERAPEUTIC AGENT AND ANTIVIRAL AGENT TOXICITY WITH ACYLATED PYRIMIDINE NUCLEOSIDES | PRO NEURON INC (US) | 1996-01-10 | — | — | EP | disclosed |
| EP-0679160-A1 | PYRIMIDINE NUCLEOTIDE PRECURSORS FOR TREATMENT OF SYSTEMIC INFLAMMATION AND INFLAMMATORY HEPATITIS | PRO-NEURON, INC. (US) | 1995-11-02 | — | — | EP | disclosed |
| WO-1994013687-A1 | PYRIMIDINE NUCLEOTIDE PRECURSORS FOR TREATMENT OF SYSTEMIC INFLAMMATION AND INFLAMMATORY HEPATITIS | PRO-NEURON, INC. (US) | 1994-06-23 | — | — | WO | disclosed |
| EP-0594667-A1 | TREATMENT OF CHEMOTHERAPEUTIC AGENT AND ANTIVIRAL AGENT TOXICITY WITH ACYLATED PYRIMIDINE NUCLEOSIDES | PRO-NEURON, INC. (US) | 1994-05-04 | — | — | EP | disclosed |
| EP-0570519-A1 | OXYPURINE NUCLEOSIDES AND THEIR CONGENERS, AND ACYL DERIVATIVES THEREOF, FOR IMPROVEMENT OF HEMATOPOIESIS | PRO-NEURON, INC. (US) | 1993-11-24 | — | — | EP | disclosed |
| WO-1993001202-A1 | TREATMENT OF CHEMOTHERAPEUTIC AGENT AND ANTIVIRAL AGENT TOXICITY WITH ACYLATED PYRIMIDINE NUCLEOSIDES | PRO-NEURON, INC. (US) | 1993-01-21 | — | — | WO | disclosed |
| WO-1992013561-A1 | OXYPURINE NUCLEOSIDES AND THEIR CONGENERS, AND ACYL DERIVATIVES THEREOF, FOR IMPROVEMENT OF HEMATOPOIESIS | PRO-NEURON, INC. (US) | 1992-08-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040235782-A1 | Oxypurine nucleosides and their congeners, and acyl derivatives thereof, for improvement of hematopoiesis | TPMT, NUDT1, ENTPD5 | ALDH1A1 220/4885TSHR 4828/4885 |
| US-20030212036-A1 | Pyrimidine nucleotide precursors for treatment of systemic inflammation and inflammatory heptitis | UMPS, TYMP, PNP | ALDH1A1 1190/4885TSHR 4359/4885 |
| US-20040220134-A1 | Pyrimidine nucleotide precursors for treatment of systemic inflammation and inflammatory hepatitis | UMPS, PNP, TYMP | ALDH1A1 1187/4885TSHR 4085/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.